Epileptogenic	epileptogenic	O	O	O	O
activity	activity	O	O	O	O
of	of	O	O	O	O
folic	folic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
after	after	O	O	O	O
drug	drug	O	O	O	O
induces	induces	O	O	O	O
SLE	sle	O	O	OTHERS	I
(	(	O	O	O	O
folic	folic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
epilepsy)OBJECTIVE	epilepsy)objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
study	study	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
folic	folic	O	O	O	O
acid-containing	acid-containing	O	O	O	O
multivitamin	multivitamin	O	O	O	O
supplementation	supplementation	O	O	O	O
in	in	O	O	O	O
epileptic	epileptic	O	DISEASE	OTHERS	I
women	women	O	O	O	O
before	before	O	O	O	O
and	and	O	O	O	O
during	during	O	O	O	O
pregnancy	pregnancy	O	O	O	O
in	in	O	O	O	O
order	order	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
structural	structural	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defects	defects	O	DISEASE	OTHERS	I
and	and	O	O	O	O
epilepsy-related	epilepsy-related	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

STUDY	study	O	O	O	O
DESIGN	design	O	O	O	O
:	:	O	O	O	O
First	first	O	O	O	O
a	a	O	O	O	O
randomised	randomised	O	O	O	O
trial	trial	O	O	O	O
,	,	O	O	O	O
later	later	O	O	O	O
periconception	periconception	O	O	O	O
care	care	O	O	O	O
including	including	O	O	O	O
in	in	O	O	O	O
total	total	O	O	O	O
12225	12225	O	O	O	O
females	females	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Of	of	O	O	O	O
60	60	O	O	O	O
epileptic	epileptic	O	DISEASE	OTHERS	I
women	women	O	O	O	O
with	with	O	O	O	O
periconceptional	periconceptional	O	O	O	O
folic	folic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
0.8	0.8	O	O	O	O
mg)-containing	mg)-containing	O	O	O	O
multivitamin	multivitamin	O	O	O	O
supplementation	supplementation	O	O	O	O
,	,	O	O	O	O
no	no	O	O	O	O
one	one	O	O	O	O
developed	developed	O	O	O	O
epilepsy-related	epilepsy-related	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
periconception	periconception	O	O	O	O
period	period	O	O	O	O
.	.	O	O	O	O

One	one	O	O	O	O
epileptic	epileptic	O	DISEASE	OTHERS	I
woman	woman	O	O	O	O
delivered	delivered	O	O	O	O
a	a	O	O	O	O
newborn	newborn	O	O	O	O
with	with	O	O	O	O
cleft	cleft	O	DISEASE	OTHERS	I
lip	lip	O	DISEASE	OTHERS	I
and	and	O	O	O	O
palate	palate	O	O	O	O
.	.	O	O	O	O

Another	another	O	O	O	O
patient	patient	O	O	O	O
exhibited	exhibited	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
cluster	cluster	O	O	O	O
of	of	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
after	after	O	O	O	O
the	the	O	O	O	O
periconception	periconception	O	O	O	O
period	period	O	O	O	O
using	using	O	O	O	O
another	another	O	O	O	O
multivitamin	multivitamin	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
22-year-old	22-year-old	O	O	O	O
epileptic	epileptic	O	DISEASE	OTHERS	I
woman	woman	O	O	O	O
was	was	O	O	O	O
treated	treated	O	O	O	O
continuously	continuously	O	O	O	O
by	by	O	O	O	O
carbamazepine	carbamazepine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
a	a	O	O	O	O
folic	folic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
mg)-containing	mg)-containing	O	O	O	O
multivitamin	multivitamin	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
20th	20th	O	O	O	O
week	week	O	O	O	O
of	of	O	O	O	O
gestation	gestation	O	O	O	O
.	.	O	O	O	O

She	she	O	O	O	O
developed	developed	O	O	O	O
status	status	O	DISEASE	OTHERS	I
epilepticus	epilepticus	O	DISEASE	OTHERS	I
and	and	O	O	O	O
later	later	O	O	O	O
symptoms	symptoms	O	O	O	O
of	of	O	O	O	O
systemic	systemic	O	O	OTHERS	I
lupus	lupus	O	O	OTHERS	I
erythematodes	erythematodes	O	O	OTHERS	I
.	.	O	O	O	O

Her	her	O	O	O	O
pregnancy	pregnancy	O	O	O	O
ended	ended	O	O	O	O
with	with	O	O	O	O
stillbirth	stillbirth	O	O	OTHERS	I
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
epileptic	epileptic	O	DISEASE	OTHERS	I
pregnant	pregnant	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
autoimmune	autoimmune	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
(	(	O	O	O	O
probably	probably	O	O	O	O
drug-induced	drug-induced	O	O	O	O
lupus	lupus	O	O	OTHERS	I
)	)	O	O	O	O
could	could	O	O	O	O
damage	damage	O	O	O	O
the	the	O	O	O	O
blood-brain	blood-brain	O	O	O	O
barrier	barrier	O	O	O	O
,	,	O	O	O	O
therefore	therefore	O	O	O	O
the	the	O	O	O	O
therapeutic	therapeutic	O	O	O	O
dose	dose	O	O	O	O
(	(	O	O	O	O
>	>	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
1	1	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
of	of	O	O	O	O
folic	folic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
triggered	triggered	O	O	O	O
a	a	O	O	O	O
cluster	cluster	O	O	O	O
of	of	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Physiological	physiological	O	O	O	O
dose	dose	O	O	O	O
(	(	O	O	O	O
<	<	O	O	O	O
1	1	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
of	of	O	O	O	O
folic	folic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
both	both	O	O	O	O
in	in	O	O	O	O
healthy	healthy	O	O	O	O
and	and	O	O	O	O
60	60	O	O	O	O
epileptic	epileptic	O	DISEASE	OTHERS	I
women	women	O	O	O	O
,	,	O	O	O	O
all	all	O	O	O	O
without	without	O	O	O	O
any	any	O	O	O	O
autoimmune	autoimmune	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
increase	increase	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
epileptic	epileptic	O	DISEASE	OTHERS	I
seizures	seizures	O	DISEASE	OTHERS	I
.	.	O	O	O	O

